Compare CRNC & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNC | DRTS |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.4M | 607.1M |
| IPO Year | N/A | N/A |
| Metric | CRNC | DRTS |
|---|---|---|
| Price | $7.79 | $7.07 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $11.60 | $8.00 |
| AVG Volume (30 Days) | ★ 1.1M | 522.9K |
| Earning Date | 02-04-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $315,961,000.00 | N/A |
| Revenue This Year | $27.55 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $997.91 | ★ N/A |
| Revenue Growth | ★ 29.46 | N/A |
| 52 Week Low | $5.94 | $2.30 |
| 52 Week High | $16.74 | $7.89 |
| Indicator | CRNC | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 26.05 | 55.11 |
| Support Level | $6.41 | $6.82 |
| Resistance Level | $11.05 | $7.64 |
| Average True Range (ATR) | 0.74 | 0.53 |
| MACD | -0.46 | -0.10 |
| Stochastic Oscillator | 18.58 | 54.37 |
Cerence Inc is a United States-based software company. It is involved in developing mobility-based solutions for drivers and their cars. The customers include all automobile original equipment manufacturers, or OEMs, or their tier 1 suppliers. The company's revenue is generated by selling software licenses and cloud-connected services. Geographically, it derives a majority of its revenue from the United States and also has a presence in Other Americas; Germany; Other Europe, the Middle East, Africa; Japan, and Other Asia-Pacific.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.